Mirum Q3 Sales $185.7M, Lifts 2026 Product Sales Guidance to $715-720M
MIRM sits 38% above its 52-week low of $63.232.
Summary
Mirum reported Q3 2026 net product sales of $185.7 million and raised full-year product sales guidance to $715-720 million, while quarterly operating expenses of $245.5 million left a $40.8 million net loss.
Key Events · Earnings and Guidance · MIRM
-
Q3 Product Sales Reach $185.7M
Third quarter 2026 global net product sales were $185.7 million versus $133.0 million in the year-earlier quarter, with LIVMARLI contributing $133.4 million (45% growth) and Bile Acid Medicines $52.3 million (28% growth).
-
2026 Guidance Raised to $715-720M
Full-year net product sales guidance was increased to $715 million to $720 million on the back of the Q3 result.
-
Quarterly Net Loss of $40.8M
Total operating expenses of $245.5 million, including $13.5 million of non-recurring acquired IPR&D, drove a $40.8 million net loss for the quarter.
-
Convertible Notes Cut by $20M
Mirum repurchased $20.0 million principal of its 4.00% convertible senior subordinated notes due 2029, roughly 25% of the outstanding notes; cash, equivalents and investments stood at $500.5 million at September 30, 2026.
Analysis · MIRM · Life Sciences
What's new here is the quarter's revenue and the raised full-year range; the pipeline recap (ATEBRIOZ approval, AZURE-1, EXPAND) was already disclosed in September and October filings. Sales of $185.7 million against $133.0 million a year earlier put the company on pace for the higher guidance, and the balance sheet still carries $500.5 million of cash and investments after a $20.0 million convertible note repurchase. Cost is the offset: operating expenses of $245.5 million produced a $40.8 million quarterly net loss, so the growth story still runs at a loss while the company funds five planned approvals and label expansions.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MIRM was trading at $87.03 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.7B. The 52-week trading range was $63.23 to $130.00. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.